Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension
NCT ID: NCT02572765
Last Updated: 2022-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2018-01-02
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms
NCT06371573
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
NCT06813742
Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network
NCT07203495
Early Versus Late FDG-PET/CT in Bladder Cancer
NCT03065725
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normotensive
Normotensive subjects
PET/CT scan
PET/CT scan
Hypertensive
Hypertensive subjects
PET/CT scan
PET/CT scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/CT scan
PET/CT scan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age ≥ 30 and ≤ 85 years
* absence of acute cardio/cerebrovascular disease (myocardial infarction, stroke, transient ischemic attack, revascularization)
* absence of acute or chronic inflammatory or autoimmune disease
* diagnosis of presence/absence of hypertension, on the basis of documented medical history
Exclusion Criteria
* atrial fibrillation
* use of anti-inflammatory drugs in the week preceding the FDG-PET/CT imaging
* chronic use of anti-inflammatory drugs
30 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neuromed IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giuseppe Lembo
prof. Giuseppe Lembo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Neuromed
Pozzilli, (IS), Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LMB05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.